World-First Phase I Clinical Trial for CRISPR-Cas9 PD-1-Edited T-Cells in Advanced Nonsmall Cell Lung Cancer

Qian Liu

DOI: https://doi.org/10.1055/s-0040-1721451

2020-01-01

Global Medical Genetics

Abstract:Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths worldwide in 2020.[1] It poses a significant economic burden in developing countries, especially in China.[2] About 80 to 85% of lung cancers are non–small cell lung cancer (NSCLC).[3] The majority of NSCLC patients will be diagnosed with advanced-stage disease. Therefore, the conventional treatment options, including surgery, chemotherapy, and radiotherapy, are unable to result in complete cures. The prognosis of advanced NSCLC remains poor despite years of research into novel combinations of chemotherapy.